Albireo Pharma (ALBO) Announces Earnings Results, Misses Expectations By $0.02 EPS

Albireo Pharma (NASDAQ:ALBO) posted its earnings results on Thursday. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.37) by ($0.02), Morningstar.com reports. The business had revenue of $0.57 million for the quarter, compared to analyst estimates of $1.20 million. Albireo Pharma had a negative return on equity of 44.88% and a negative net margin of 2,900.81%.

NASDAQ ALBO opened at $34.45 on Friday. Albireo Pharma has a fifty-two week low of $19.10 and a fifty-two week high of $37.95.

A number of analysts recently issued reports on ALBO shares. BidaskClub raised shares of Albireo Pharma from a “strong sell” rating to a “sell” rating in a research report on Thursday, January 31st. ValuEngine raised shares of Albireo Pharma from a “hold” rating to a “buy” rating in a research report on Thursday, February 28th. HC Wainwright started coverage on shares of Albireo Pharma in a research report on Thursday, February 28th. They set a “buy” rating and a $62.00 target price for the company. Wedbush set a $69.00 target price on shares of Albireo Pharma and gave the stock a “buy” rating in a research report on Sunday, March 10th. Finally, Zacks Investment Research downgraded shares of Albireo Pharma from a “hold” rating to a “sell” rating in a research report on Monday, March 11th. One analyst has rated the stock with a sell rating, four have given a buy rating and two have assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $54.25.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ALBO. Wells Fargo & Company MN boosted its holdings in Albireo Pharma by 315.3% in the 3rd quarter. Wells Fargo & Company MN now owns 4,676 shares of the biopharmaceutical company’s stock worth $154,000 after acquiring an additional 3,550 shares during the period. Bank of New York Mellon Corp boosted its holdings in Albireo Pharma by 8.6% in the 3rd quarter. Bank of New York Mellon Corp now owns 35,023 shares of the biopharmaceutical company’s stock worth $1,154,000 after acquiring an additional 2,760 shares during the period. BlackRock Inc. boosted its holdings in Albireo Pharma by 11.4% in the 3rd quarter. BlackRock Inc. now owns 584,177 shares of the biopharmaceutical company’s stock worth $19,255,000 after acquiring an additional 59,901 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Albireo Pharma by 518.1% in the 3rd quarter. Dimensional Fund Advisors LP now owns 82,833 shares of the biopharmaceutical company’s stock worth $2,730,000 after acquiring an additional 69,431 shares during the period. Finally, MetLife Investment Advisors LLC boosted its holdings in Albireo Pharma by 55.1% in the 3rd quarter. MetLife Investment Advisors LLC now owns 7,312 shares of the biopharmaceutical company’s stock worth $241,000 after acquiring an additional 2,599 shares during the period. Hedge funds and other institutional investors own 66.91% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Albireo Pharma (ALBO) Announces Earnings Results, Misses Expectations By $0.02 EPS” was published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://transcriptdaily.com/2019/05/11/albireo-pharma-albo-announces-earnings-results-misses-expectations-by-0-02-eps.html.

About Albireo Pharma

Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.

Recommended Story: Investing strategies using the yield curve

Earnings History for Albireo Pharma (NASDAQ:ALBO)

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.